Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.67 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.54 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.54 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.54 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223247 | 0.90 | CXCR2 (0.67) | CXCR2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL3227775 | 0.88 | CXCR2 (0.72) | CXCR2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL3225492 | 0.88 | CXCR2 (0.64) | CXCR2KCNQ3KCNQ2POLBNPC1 | |
| SCHEMBL3225333 | 0.84 | CXCR2 (0.71) | CXCR2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL3221365 | 0.84 | CXCR2 (0.63) | CXCR2KCNQ3KCNQ2ALDH1A1NPC1 | |
| SCHEMBL3228211 | 0.82 | CXCR2 (0.60) | CXCR2ALDH1A1POLBNPC1RAB9A | |
| SCHEMBL3228209 | 0.81 | CXCR2 (1.00) | CXCR2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL3218503 | 0.80 | CXCR2 (0.64) | CXCR2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL3228267 | 0.80 | CXCR2 (0.68) | CXCR2POLBNPC1RAB9AMAPT | |
| SCHEMBL3225340 | 0.79 | CXCR2 (0.71) | CXCR2ALDH1A1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | UCB SA (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7141590-B2 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | UCB SA (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LIMITED (GB) | 2005-02-03 | — | — | US | disclosed |
| WO-2002053544-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | DARWIN DISCOVERY LTD. (GB) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | NNT, NAPRT, NNMT | CXCR2 1447/4885KCNQ3 1517/4885KCNQ2 1152/4885 |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | CXCR2 1447/4885KCNQ3 1517/4885KCNQ2 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.